William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.
Christopher Willett, MD, of Duke Cancer Center, discusses short and long courses of treatment, neoadjuvant chemotherapy with or without radiation, and organ preservation without surgery.
Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center, discusses ways to prevent advanced-phase chronic myeloid leukemia through adherence to prescribed treatment and routine monitoring of disease burden.
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center, discusses the multiple services required to best treat this rare cancer.
Kenneth Anderson, MD, of Dana-Farber Cancer Institute, discusses how the many advances in the treatment of multiple myeloma affect current and future clinical practice.
Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.
